Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

In ES-SCLC presenting with limited asymptomatic brain metastases and treated upfront with systemic therapy alone (carbo/etop/atezo), how would you approach the brain if MRI shows PR after a few cycles?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Dana Farber/Brigham and Women's Cancer Center

In our practice, we would typically watch such a patient on systemic therapy. However, we would stress the need for vigilant monitoring and likely administration of RT (SRS ideally) at the carbo/etop/atezo transition to atezo monotherapy, given the poor intracranial efficacy of the maintenance syste...

How do you manage perioperative anticoagulation for a patient with a history of recent, surgically provoked VTE?

1 Answers

Mednet Member
Mednet Member
Hematology · Medical University of South Carolina

In most cases, bridging is rarely indicated because the bleeding risk usually outweighs the risk of VTE recurrence during a short (1–2 day) interruption of anticoagulation. However, after a recent VTE (defined as <3 months), the estimated risk of VTE recurrence is high (>15–20% per year) (still low ...

Does receiving IVIG confound the result of SPEP and/or UPEP?

4
2 Answers

Mednet Member
Mednet Member
Hematology · John Theurer Cancer Center Hackensack Univ Med Center

IVIG being a product of polyclonal immunoglobulins may ‘produce’ a monoclonal spike if the AUC is falsely calculated by the reader. IFE usually shows polyclonal banding but every now and then a monoclonal band is picked up. Being an IgG molecule with a 21 day halflife; and with the assumption that i...

How would you approach a patient with vitreoretinal lymphoma without CNS or systemic involvement?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

The optimal treatment approach for primary intraocular lymphoma is debated. This is a rare disease with only small retrospective series guiding therapy. There is no clear superior treatment approach in the literature. In clinical practice, younger patients are often treated initially with high-dose ...

Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?

5
2 Answers

Mednet Member
Mednet Member
Infectious Disease · Harbor - UCLA Medical Center

PCV-21 was recently approved by the FDA and supported by ACIP. At this early stage (August 2024), CDC has not finalized guidance on PCV-21, so we do not know how the vaccine schedule will be changed. An important distinction is that PCV-21 covers different serotypes of pneumococcus, as outlined in t...

Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?

5
2 Answers

Mednet Member
Mednet Member
Infectious Disease · Harbor - UCLA Medical Center

PCV-21 was recently approved by the FDA and supported by ACIP. At this early stage (August 2024), CDC has not finalized guidance on PCV-21, so we do not know how the vaccine schedule will be changed. An important distinction is that PCV-21 covers different serotypes of pneumococcus, as outlined in t...

When would you phlebotomize patients with secondary hemochromatosis, such as due to NAFLD/cirrhosis?

3
1 Answers

Mednet Member
Mednet Member
Hematology · Weill Cornell Medical College and Houston Methodist Hospital

My simple answer is “rarely, if ever” (but it can get much more complicated). Related to hepcidin changes, patients with chronic liver disease frequently have elevated serum ferritin and transferrin saturation, more so with alcoholic liver disease and non-alcoholic fatty liver disease. It is far fro...

How would you treat AML in a pregnant patient at 12 weeks' gestation?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Chicago

My answer is under the assumption that, after a multi-disciplinary discussion with the patient, oncology/leukemia team, and maternal fetal medicine, the objective is to initiate AML-directed therapy while maintaining the pregnancy. The highest risk of deleterious impact to the fetus from chemotherap...

How would you treat AML in a pregnant patient at 12 weeks' gestation?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Chicago

My answer is under the assumption that, after a multi-disciplinary discussion with the patient, oncology/leukemia team, and maternal fetal medicine, the objective is to initiate AML-directed therapy while maintaining the pregnancy. The highest risk of deleterious impact to the fetus from chemotherap...

If adjuvant radiation is offered to an elderly patient with H&N SCC s/p Mohs surgery who is planned for multi-stage reconstruction of the defect with plastic surgery, when should adjuvant radiation be started?

5
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · UTMB

Tumor control comes first. If the surgical defect is such that reconstruction is required, it is even more imperative to focus on the above principle, as a recurrence would almost certainly risk ruining the entire collective effort. Vascular flaps could be safely performed post-RT in most cases by s...